NEW BRUNSWICK
FIRAZYR is covered by the New Brunswick Drug Plans Formulary (Special Authorization)
Eligibility
For FIRAZYR to be eligible for coverage under the New Brunswick Drugs Plan, prescribers must submit a request for special authorization and the request must be approved before the patient fills the prescription. Deductibles may apply. For more information concerning the reimbursement process, contact OnePath®.
Reimbursement Criteria
We are pleased to inform you that FIRAZYR (icatibant acetate) is reimbursed in New Brunswick for your hereditary angioedema (HAE) patients who meet the following criteria:
For the treatment of acute attacks of type I or type II HAE in adults with lab confirmed C1-esterase inhibitor deficiency if the following conditions are met:
- Non-laryngeal attacks of at least moderate severity, OR
- Acute laryngeal attacks
Clinical Notes:
- Using more than three doses in a 24-hour period is not recommended
- The safety of more than eight injections per month has not been investigated in clinical trials
Claim Notes:
- Must be prescribed by, or in consultation with, physicians experienced in the treatment of HAE
- Coverage is limited to a single dose per attack
- The maximum quantity that may be dispensed at one time is two doses
Duration of Approval: Lifetime
OnePath® Patient Support Program will help navigate insurance coverage and access reimbursement to medication through private and public insurance companies.
Source: New Brunswick Drug Plans Formulary. April 2022.
https://www2.gnb.ca/content/dam/gnb/Departments/h-s/pdf/en/NBDrugPlan/NewBrunswickDrugPlansFormulary.pdf